Scanning and combinatorial library services – Save 20% with code TRY-BXPLIB-20

Press + news

March 10, 2021

Codex DNA Releases World’s First Synthetic Genomes for Emerging SARS-CoV-2 Variants

New synthetic genomes of the UK and South Africa variants will accelerate discovery and development for vaccines and therapeutics

SAN DIEGO — March 5, 2021 — Codex DNA, Inc., today announced the release of the world’s first full-length synthetic genomes for two emerging variants of the SARS-CoV-2 virus. The new genomes include the B.1.1.7 variant that initially emerged in…


December 2, 2020

Codex DNA Releases New Synthetic Genomes for the Fight Against COVID-19

Seven new SARS-CoV-2 genomes will accelerate vaccine and therapy development

SAN DIEGO – (GLOBE NEWSWIRE) – Codex DNA, Inc. today announced the release of seven new synthetic SARS-CoV-2 genomes for use in the development of vaccines, therapeutics, and diagnostics to help in the COVID-19 pandemic response. With our BioXp™ 3250 system,…


August 25, 2020

Codex DNA Demonstrates Momentum Toward Mission of Building World’s First Vaccine Printer and Global Vaccine Network

The Digital-to-Biological Converter will enable printing life-saving vaccines on a global scale using synthetic DNA to stop future pandemics

SAN DIEGO – (GLOBE NEWSWIRE) – Codex DNA, Inc., creators of the world’s first fully automated system for high-throughput writing of DNA, today announced critical advancements in its development of the Digital-to-Biological Converter™ (DBC) platform. The platform will enable the direct…


August 18, 2020

Codex DNA Launches New Automated Synthetic Biology Workstation for Commercial Use

The new BioXp™ 3250 system – a fully automated, benchtop platform for synthetic biology workflows – dramatically accelerates the development of critical new vaccines and biologics

SAN DIEGO – (GLOBE NEWSWIRE) – Today, Codex DNA, Inc., creators of the world’s first fully automated system for high-throughput DNA printing, announced the introduction of their next-generation platform, the BioXp™ 3250 system. This system reduces the timelines for identifying vaccine and…


July 16, 2020

Codex DNA Releases New Synthetic SARS-CoV-2 Genome for COVID-19 Vaccine and Therapeutic Research

New version represents dominant variant of the virus responsible for COVID-19 to enable relevant research and development of clinical treatments

SAN DIEGO – (GLOBE NEWSWIRE) – Codex DNA, Inc., today announced the release of a new synthetic SARS-CoV-2 genome developed to accelerate research on the latest and the most dominant strain of the SARS-CoV-2 virus responsible for the COVID-19 pandemic. The…


April 9, 2020

Codex DNA announces 8 new products to support the scientific community’s battle against COVID-19

Pioneering synthetic DNA company releases a wide range of antigen panels, synthetic DNA parts, and vaccine scaffolds to expedite vaccine development, drug discovery, and diagnostics

SAN DIEGO – (GLOBE NEWSWIRE) – Codex DNA, Inc., creators of the world’s first fully automated system for high-throughput writing of DNA, the BioXp™ 3200 system, today announced a newly developed and released suite of products and services designed to accelerate…


April 6, 2020

SGI-DNA is now Codex DNA

Pioneering DNA synthesis company — inventor of the Gibson Assembly® method and the BioXp™ system — furthers its mission to empower researchers in moving “from reading DNA to writing and printing DNA”

SAN DIEGO – (GLOBE NEWSWIRE) – SGI-DNA, Inc., creators of the world’s first fully automated system for high-throughput writing of DNA, the BioXp™ 3200 system, today announced the business rebrand to Codex DNA, Inc. The rebrand signifies and solidifies the company’s…


February 18, 2020

SGI-DNA Equipping Researchers With Critical Tools to Combat Coronavirus Disease (COVID-2019)

Synthetic biology company taking major steps in worldwide effort to put a stop to the SARS-CoV-2 (formerly known as 2019-nCoV) outbreak, including co-funding purchases of BioXp™ 3200 System. SGI-DNA is enabling researchers to quickly print DNA required to discover vaccines and therapeutics.

SAN DIEGO – (BUSINESS WIRE) – SGI-DNA, creators of the BioXp™ 3200 System and Gibson Assembly® Reagents, announces a focused effort to empower organizations to accelerate research focused on creating vaccines for SARS-CoV-2. SGI-DNA is building resources to support partners in the…


January 31, 2020

SGI-DNA Launches Vmax™ X2, the Most Innovative Product in the Competent Cells Market Since the Discovery of E. coli

Pioneering synthetic biology company, SGI-DNA, releases a new protein expression system, accelerating research into vaccines and personalized medicines by delivering up to 4x more soluble protein than traditional E. coli methods in half the time

SAN DIEGO – (BUSINESS WIRE) – SGI-DNA, creators of the BioXp™ 3200 System and Gibson Assembly® Reagents, has launched Vmax™ X2 Competent Cells, designed to generate two to four times more soluble protein in half of the time of current methods…


December 23, 2019

SGI-DNA Appoints Brian Donnelly as Chief Commercial Officer

SAN DIEGO – (BUSINESS WIRE) – SGI-DNA, Inc., a company dedicated to developing transformative synthetic genomics technologies and revolutionary DNA data storage solutions, today announced the appointment of Brian Donnelly to the newly created position of Chief Commercial Officer. Mr. Donnelly…


November 19, 2019

SGI-DNA Launches Gibson Assembly® RapidAMP™ Technology for its BioXp™ Gene Builder

The technology allows for mammalian transfection-ready DNA constructs to be synthesized, assembled into custom vectors, and amplified in a single day on the BioXp™ Gene Builder, eliminating the need to clone and copy DNA in E. coli

SAN DIEGO – (BUSINESS WIRE) – SGI-DNA announces the launch of Gibson Assembly® RapidAMP™ technology—a novel approach that allows for cell-free synthesis and amplification of transfection-ready quantities of synthetic DNA. The application has been integrated onto the BioXp™ 3200 Gene Builder and…


October 1, 2019

Gibson Assembly® Advances Field of DNA Digital Data Storage

Gibson Assembly strategy successfully employed to significantly increase the throughput of DNA data storage and retrieval

SAN DIEGO – (BUSINESS WIRE) – Researchers from the University of Washington and Microsoft announced a DNA assembly strategy for nanopore data storage, reporting that the Gibson Assembly® Method was exceptionally effective in retrieving information stored in DNA. The strategy successfully…


September 9, 2019

SGI-DNA Secures $25 Million Series A Financing to Support Commercial Launch

Company using capital for the global commercial launch of the BioXp™ 3200 Gene Builder — a fully automated gene synthesis and cloning platform powered by Gibson Assembly® Technology — and execution of its product roadmap for automated printing of biological materials and DNA data storage

SAN DIEGO – (BUSINESS WIRE) – SGI-DNA, a company dedicated to developing transformative synthetic genomics technologies and revolutionary DNA data storage solutions, has completed a $25 million Series A financing round led by Northpond Ventures, with participation from Oxford Finance…


August 26, 2019

SGI-DNA Launches Multi-Tile Assembly Cloning (MTAC) Application for its BioXp™ 3200

MTAC application leverages Gibson Assembly® Technology to advance automated protein and antibody engineering capabilities and custom vector printing

SAN DIEGO – (BUSINESS WIRE) – SGI-DNA announces the launch of the Multi-Tile Assembly Cloning (MTAC) application for its BioXp™ 3200 Gene Builder, providing scientists with the ability to synthesize two genes and clone them with an optional constant fragment…


Contact us

The expertise of our scientists, engineers, and supporting teams is always available. Or call us: 858.228.4115

By clicking Submit, you agree that Codex DNA may use this information to contact you about our programs, products, or services. You may opt out at any time.

Your personal data is handled according to our privacy policy. In addition, if you are located within a distributor territory, you may be contacted directly by them. We never sell your data to anyone.